Stockholders’ Equity - Schedule of Common Stock Warrant Activity (Details) $ / shares in Units, $ in Thousands |
6 Months Ended |
|---|---|
|
Jun. 30, 2021
USD ($)
$ / shares
shares
| |
| Equity [Abstract] | Â |
| Outstanding at January 1, 2021 | shares | 3,082,987 |
| Weighted-average exercise price per share, outstanding | $ / shares | $ 3.82 |
| Intrinsic value, outstanding | $ | $ 37,379 |
| Exercised | shares | (1,593,971) |
| Weighted-average exercise price per share, exercised | $ / shares | $ 3.07 |
| Outstanding at June 30, 2021 | shares | 1,489,016 |
| Outstanding at June 30, 2021 | $ / shares | $ 4.62 |
| Intrinsic value, outstanding | $ | $ 21,653 |
| X | ||||||||||
- Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the other than stock option plan. No definition available.
|
| X | ||||||||||
- Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the other than stock option plan. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options. No definition available.
|